The calculation workspace
GLP-1 BMI & Eligibility Checker
Calculate your Body Mass Index (BMI) and see how it compares with FDA-approved label indications for Wegovy, Zepbound, Foundayo, Ozempic, and Mounjaro.
Summarizes published DailyMed prescribing information only. Only a licensed prescriber can determine whether a medication is medically appropriate and safe for you.
1. Check BMI Against FDA GLP-1 Label Criteria
| Medication | FDA label criteria | Based on inputs |
|---|
2. Key Label Contraindications to Review with a Clinician
- Boxed warning (semaglutide & tirzepatide): Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pregnancy & planning pregnancy: Weight-reduction GLP-1 labels advise against use during pregnancy and recommend discontinuing semaglutide at least 2 months before a planned pregnancy.
- Prior history of pancreatitis, severe GI disease, or diabetic retinopathy: Requires individualized medical evaluation before starting therapy.
4. GLP-1 BMI & Eligibility FAQ
What BMI is required for Wegovy or Zepbound?
Under FDA prescribing labels for chronic weight management, Wegovy (semaglutide) and Zepbound (tirzepatide) are indicated for adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
Does Ozempic or Mounjaro have a weight-loss BMI threshold?
No. Ozempic and Mounjaro are FDA-approved for adults with type 2 diabetes (and cardiovascular risk reduction, plus CKD protection for Ozempic) rather than weight loss alone. Their sister brands Wegovy and Zepbound carry the weight-management labels.
If my BMI meets the FDA label criteria, does that guarantee a prescription or insurance coverage?
No. Prescribing requires a clinician to review your full medical history and rule out contraindications (such as a personal or family history of medullary thyroid carcinoma or MEN 2). Insurance plans also frequently apply stricter prior-authorization rules than the FDA label.
Are BMI thresholds different for Asian populations?
The World Health Organization and American Diabetes Association note that many Asian populations experience elevated cardiometabolic risk at lower BMIs (overweight at ≥ 23 kg/m² and obesity at ≥ 27.5 kg/m²). However, current US FDA drug labels still list 27 and 30 kg/m² as standard cutoffs.